ProMIS Neurosciences (PMN)
NASDAQ:PMN
Want to see PMN full AI Analyst Report?
Top Page
ProMIS Neurosciences
(NASDAQ:PMN)
Select Model
Select Model
Rating:43Neutral
Price Target:
$10.00
▲(23.15% Upside)
Action:Reiterated
Date:05/14/26
The score is primarily pressured by weak financial performance (no revenue, large losses, and continued cash burn). Technicals also detract given the stock is trading below key moving averages with negative MACD. Valuation provides limited support because earnings are negative and no dividend yield is available.
Positive Factors
Debt-free balance sheet
A debt-free capital structure and a meaningful equity base reduce financial risk and increase strategic flexibility. For a clinical-stage biotech, this lowers near-term insolvency risk and gives management room to prioritize R&D and trial completion without immediate pressure to service borrowings.
Negative Factors
Pre-revenue with large losses
Being pre-revenue with sustained multi-year net losses means the company's long-term viability depends on R&D success or continued external funding. Persistent operating deficits create recurring financing needs and make strategic outcomes (trial success or partnerships) determinative for future cash flows.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A debt-free capital structure and a meaningful equity base reduce financial risk and increase strategic flexibility. For a clinical-stage biotech, this lowers near-term insolvency risk and gives management room to prioritize R&D and trial completion without immediate pressure to service borrowings.
Read all positive factors
ProMIS Neurosciences (PMN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$22.36M
Dividend YieldN/A
Average Volume (3M)819.50K
Price to Earnings (P/E)―
Beta (1Y)0.08
Revenue GrowthN/A
EPS Growth-1753.64%
CountryUS
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-23.59
Shares Outstanding2,152,397
10 Day Avg. Volume1,049,009
30 Day Avg. Volume819,497
Financial Highlights & Ratios
PEG Ratio0.33
Price to Book (P/B)-9.53K
Price to Sales (P/S)0.00
P/FCF Ratio-0.43
Enterprise Value/Market Cap-2.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda1.22
Forecast
1Y Price Target
$35.00Price Target Upside331.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.38
Revenue Forecast (FY)N/A
ProMIS Neurosciences Business Overview & Revenue Model
Company Description
ProMIS Neurosciences (PMN) is a biotechnology company focused on the discovery and development of precision therapeutics for neurodegenerative diseases, particularly Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company utilizes...
How the Company Makes Money
null...
ProMIS Neurosciences Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ― |
| Gross Profit | 0.00 | 0.00 | 0.00 | -10.44M | 0.00 | ― |
| EBITDA | -41.02M | -39.72M | 2.86M | -17.81M | -17.77M | -9.33M |
| Net Income | -40.62M | -39.72M | 2.78M | -17.51M | -18.06M | ― |
Balance Sheet | ||||||
| Total Assets | 67.41M | 9.18M | 18.91M | 13.62M | 9.38M | 22.44M |
| Cash, Cash Equivalents and Short-Term Investments | 63.85M | 6.15M | 13.32M | 12.63M | 8.01M | 21.48M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.94M |
| Total Liabilities | 6.69M | 10.44M | 2.42M | 9.87M | 11.20M | 15.28M |
| Stockholders Equity | 60.72M | -1.26M | 16.49M | 3.75M | -1.82M | 7.16M |
Cash Flow | ||||||
| Free Cash Flow | -35.47M | -28.12B | -27.18M | -10.84M | -17.04M | -9.45M |
| Operating Cash Flow | -35.47M | -28.12B | -27.18M | -10.84M | -17.03M | -9.44M |
| Investing Cash Flow | -703.00 | -702.00K | -693.00 | -1.35K | -1.98K | 95.93K |
| Financing Cash Flow | 91.07M | 20.94B | 27.88M | 17.75M | 6.49M | 25.63M |
ProMIS Neurosciences Technical Analysis
Negative
8.12
Price Trends
16.54
Negative
12.72
Negative
12.75
Negative
Market Momentum
-1.50
Positive
36.27
Neutral
40.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PMN, the sentiment is Negative. The current price of 8.12 is below the 20-day moving average (MA) of 13.39, below the 50-day MA of 16.54, and below the 200-day MA of 12.75, indicating a bearish trend. The MACD of -1.50 indicates Positive momentum. The RSI at 36.27 is Neutral, neither overbought nor oversold. The STOCH value of 40.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PMN.
ProMIS Neurosciences Risk Analysis
ProMIS Neurosciences disclosed 76 risk factors in its most recent earnings report. ProMIS Neurosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ProMIS Neurosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $242.73M | -0.53 | 359.80% | ― | ― | -3629.03% | |
46 Neutral | $7.71M | -1.04 | -49.00% | ― | 11.90% | 43.46% | |
46 Neutral | $71.14M | ― | -159.43% | ― | ― | 20.55% | |
44 Neutral | $29.22M | ― | 9999.00% | ― | ― | ― | |
43 Neutral | $22.36M | -2.51 | 9999.00% | ― | ― | -1753.64% |
* Healthcare Sector Average
PMN
ProMIS Neurosciences
10.39
-2.11
-16.88%
NERV
Minerva Neurosciences
5.21
3.76
259.31%
IMRN
Immuron
1.01
-0.60
-37.23%
ANVS
Annovis Bio
2.06
-0.06
-2.83%
NRSN
Neurosense Therapeutics Ltd.
0.83
-0.54
-39.71%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.